List view / Grid view
The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene...
The BBA, the representative group of biosimilar manufacturers in the UK, has announced that Kavya Gopal will become its new chair with immediate effect...
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review...
13 October 2017 | By Thermo Fisher Scientific
In this webinar, theory and practice of HDX-MS will be discussed in conjunction with the topics of pharmaceutical industry...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
Researchers have compared the regulatory authorities responsible for approving drugs and medical products to verify their effectiveness and safety...
Bringing a biosimilar from early development to market is a risky endeavour say Magnus Franzen (left) and Chris Isler, biosimilar experts at PA Consulting Group...
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine...
The Association for Accessible Medicines (AAM) applauded the US Supreme Court’s decision this week in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.
The development and production of antibody biopharmaceuticals and biosimilars require specific chromatographic tools for efficient purification and QC analysis to improve process economics, safety, and time-to-market.
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
1 June 2017 | By Niamh Marriott, Junior Editor
The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines...
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
